Accessibility Menu
Cell MedX logo

Cell MedX(OTC) CMXC

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2013)-82%
5 Year-93%
1 Year-43%
1 Month-21%
N/A
Cell MedX last closing stock price
MetricPriceDate
Last closeUSD 0.282026-07-27
Cell MedX stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.282026-07-09
1 month-21.14%USD 0.352026-06-26
3 month-6.44%USD 0.302026-04-28
Year to date-31%USD 0.402025-12-31
1 year-42.5%USD 0.482025-07-25
3 year-8%USD 0.302023-07-27
5 year-92.67%USD 3.772021-07-28
Since inception-81.6%USD 1.502013-08-29

Cell MedX Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$885.25K

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Oct 15, 2024

CMXC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cell MedX

Stimcell Energetics makes devices for pain relief and wellness at home or in clinics. Its products help people manage pain from conditions like diabetes or Parkinson’s. The company’s technology uses gentle electrical currents to target discomfort in daily life.

Gadgets for Good: Products and Services

  • eBalance Pro System: Device for healthcare professionals to help patients manage pain in clinics. (0% of revenue in latest periods)
  • eBalance Home System: Home-use device for general wellness and temporary pain relief. (0% of revenue in latest periods)
  • eBalance Console: Central controller with three preset programs for wellness and pain management. (0% of revenue in latest periods)
  • Microcurrent Technology: Uses low-level electrical currents to target pain in areas like back or neck.
  • Product Development: Ongoing redesign to make devices smaller, more affordable, and easier for consumers.

Plot Twists: Growth and Expansion

  • Partnered with ADM Tronics Unlimited in February 2025 to redesign the eBalance device for home use.
  • Launched research with St. Boniface Hospital Albrechtsen Research Centre in December 2025 to study device effects on nerve cells.
  • Issued shares for investor relations and advisory services in 2026 to support business development.
  • Focused on U.S. market, with headquarters in Vancouver, Canada, since 2010.

What Makes Stimcell Energetics Stand Out

The company targets both professional clinics and home users with its microcurrent devices. Its partnerships aim to improve device features and affordability. Research collaborations focus on understanding how its technology affects nerve health.

Five Things You Need to Know

  • No revenue reported for QQ2 2026, QQ2 2025, or QQ2 2024.
  • Net loss was $271,498 in QQ2 2026, down 537.9% over two years.
  • Cash balance was $10,257 as of February 28, 2026, with a $1.68 million working capital deficit.
  • All financing comes from related parties, with some loans in default and interest rates up to 10%.
  • Only one full-time employee as of the latest report; market cap was $7.31 million.

Bottom Line

Stimcell Energetics develops pain relief devices but has not generated revenue. The company relies on related party funding and faces ongoing financial challenges.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

CEO

David M. Jeffs

Website

stimcell.com

Headquarters

Carson City, NV 89706, US

CMXC Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

60.42%

Return on Capital

N/A

Return on Assets

-2564.37%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$0.00

Operating Income

$73.85K

EBITDA

-$191.76K

Operating Cash Flow

-$340.76K

Capital Expenditure

-$3.34

Free Cash Flow

-$340.76K

Cash & ST Invst.

$10.26K

Total Debt

$0.00

Cell MedX Performance Analysis

Cell MedX annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-05-31USD 6,065N/A
20232023-05-31USD 2,762-54.5%
20242024-05-31USD 0N/A
20252025-05-31USD 0N/A
Cell MedX sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-05-31N/A
Q12025-08-31N/A
Q22025-11-30N/A
Q32026-02-28N/A
Cell MedX annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-05-31USD -0.17N/A
20232023-05-31USD -0.12-29.1%
20242024-05-31USD -0.01-88.8%
20252025-05-31USD -0.03115.9%
Cell MedX sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-05-31-101.4%
Q12025-08-3130.1%
Q22025-11-30N/A
Q32026-02-2857.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

-$90.57K

+35.6%

EBITDA

$0.00

N/A

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

$10.26K

+53.6%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-25.64%

N/A

Return on Invested Capital

1.94%

N/A

Free Cash Flow

-$86.29K

-187.9%

Operating Cash Flow

-$86.29K

-187.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AMEUFAnteris Technologies Ltd
$5.70-35.81%
GREHGreen Rain Energy Holdings Inc.
$0.01-1.45%
LFLYLeafly Holdings, Inc.
$37.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOFISoFi Technologies
$15.25-0.09%
INTCIntel
$81.88-0.05%
NVDANvidia
$190.01-0.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$57.75-0.06%

Questions About CMXC

What is the current price of Cell MedX?

Cell MedX is trading at N/A per share.

What is the 52-week range for Cell MedX?

Over the past 52 weeks, Cell MedX has traded between N/A and N/A.

How much debt does Cell MedX have?

As of the most recent reporting period, Cell MedX reported total debt of $667.31K.

How much cash does Cell MedX have on hand?

Cell MedX reported $10.26K in cash and cash equivalents in its most recent financial results.

What is Cell MedX’s dividend yield?

Cell MedX does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services